Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept 50 mg Once Weekly in Moderate to Severe Plaque Psoriasis
2005-005936-29Phase 3Completed
- Sponsor
- Wyeth
- Start
- Mar 2006
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Etanercept 50 mg once weekly with Placebo (2 arms). Primary endpoint: PASI 75 response at week 12. Started Mar 2006; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2005-005936-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005936-29.